TauRx concentrates on tau pathology and has spent two decades developing treatments and diagnostics for Alzheimer’s and related neurodegenerative diseases driven by protein aggregation. Its lead program, HMTM, is being advanced toward regulatory submission and commercialisation. The company plans to submit HMTM for regulatory approval in the UK, US and Canada in 2023, with other territories to follow, and intends to pursue clinical trials in other related neurodegenerative diseases. TauRx is led by Glenn Corr (COO and Chief Business Officer) and links ongoing work with its research partnership at the University of Aberdeen. The group was established in 2002 in Singapore and maintains primary research facilities and operations in Aberdeen, UK. TauRx is a clinical-stage biopharmaceutical company developing LMTX, a tau aggregation inhibitor targeting abnormal tau fibrils implicated in Alzheimer’s disease and frontotemporal dementia. LMTX is currently in global Phase 3 clinical trials for Alzheimer’s and FTD. The company completed a US$135m equity financing to support its Phase 3 clinical program. The financing was provided through a combination of new investors and existing shareholders. TauRx was created in Singapore in 2002 as a spin-out from the University of Aberdeen. Its headquarters are in Singapore and its primary research facilities are based in Aberdeen. The company is led by co-founder and Executive Chairman Professor Claude Wischik. TauRx Pharmaceuticals Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases based on targeting aggregates of abnormal tau protein fibers inside nerve cells. Its lead compound, LMTX™, is being developed as a disease-modifying treatment for Alzheimer’s disease and behavioural-variant frontotemporal dementia. The company is conducting three Phase 3 clinical trials of LMTX™ and intends to use the new proceeds to support that ongoing program. TauRx was established in Singapore in 2002 and is led by Professor Claude Wischik, Executive Chairman and Co‑Founder. Its primary research facilities are located in Aberdeen, Scotland. The company received a USD10.5m equity investment from Dundee Corporation to fund its clinical program. TauRx Pharmaceuticals develops LMTX, a tau aggregation inhibitor (TAI) designed to dissolve tau tangles and halt their harmful effects in Alzheimer's and other tauopathies. The company is using new funding to run pivotal global Phase 3 trials after a Phase 2 in over 300 patients showed a 90% reduction in disease progression over two years. The Phase 3 program includes an 833‑patient 12‑month study, a 500‑patient 18‑month study and a 180‑patient frontotemporal dementia study, with sites across Australia, Europe, North America and Asia. TauRx was established in Singapore in 2002, with headquarters in Singapore and primary research facilities in Aberdeen, Scotland. The company has raised almost US$300M in equity since formation. As part of the transaction, Genting executives joined the board and TauRx plans a joint venture with Genting to develop clinic‑based assessment and treatment capabilities for Alzheimer's in Asia.

Total raised

$296M

Funding rounds

4

Latest round

Equity

Latest activity

Nov 2022